Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 0.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.14 | 1.91 |
NAV | ₹17.09 | ₹40.27 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1459.59 Cr | ₹5044.63 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 50.48% | 47.94% |
3 Year | - | 24.29% |
5 Year | - | 31.13% |
1 Year
3 Year
5 Year
Equity | 98.21% | 97.27% |
Cash | 1.79% | 2.73% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.48% |
Divi's Laboratories Ltd. | 7.85% |
Cipla Ltd. | 7.75% |
Lupin Ltd. | 5.80% |
Gland Pharma Ltd. | 3.99% |
Ipca Laboratories Ltd. | 3.75% |
Aster DM Healthcare Ltd. | 3.57% |
Vijaya Diagnostic Centre Ltd. | 3.54% |
Eris Lifesciences Ltd. | 3.38% |
Glenmark Pharmaceuticals Ltd. | 3.37% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.77% |
Dr. Reddy's Laboratories Ltd. | 8.48% |
Cipla Ltd. | 7.94% |
Aurobindo Pharma Ltd. | 5.04% |
Gland Pharma Ltd. | 4.38% |
Lupin Ltd. | 4.29% |
Alkem Laboratories Ltd. | 4.16% |
Zydus Lifesciences Ltd. | 3.10% |
Apollo Hospitals Enterprise Ltd. | 2.93% |
Biocon Ltd. | 2.39% |
Name | Dhruv Muchhal | Dharmesh Kakkad |
Start Date | 14 Sep 2023 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
Launch Date